NCT02858869 2026-03-09
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
Emory University
Phase 1 Completed
Clinical Trials
16 trialsNCT03873818 2026-01-09
Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03426891 2025-10-06
Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02681549 2025-08-07
Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)
Yale University
Phase 2 Completed
NCT04479241 2025-06-05
LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma
Istari Oncology, Inc.
Phase 2 Completed
NCT02311582 2025-05-29
MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas
Washington University School of Medicine
Phase 1/2 Completed
NCT03665545 2025-05-13
IMA950-106
University Hospital, Geneva
Phase 1/2 Completed
NCT02960230 2025-01-22
H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas
University of California, San Francisco
Phase 1/2 Completed
NCT03661723 2024-09-19
Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT04013672 2024-08-28
Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence
Case Comprehensive Cancer Center
Phase 2 Completed
NCT03012620 2024-02-28
AcSé
UNICANCER
Phase 2 Completed
NCT02313272 2023-10-23
Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT03726515 2023-06-22
CART-EGFRvIII + Pembrolizumab in GBM
University of Pennsylvania
Phase 1 Completed
NCT02798406 2021-07-15
CAPTIVE
DNAtrix, Inc.
Phase 2 Completed
NCT02085070 2021-03-24
MK-3475 in Melanoma and NSCLC Patients With Brain Metastases
Yale University
Phase 2 Completed
NCT02337491 2020-12-22
Pembrolizumab +/- Bevacizumab for Recurrent GBM
Dana-Farber Cancer Institute
Phase 2 Completed